RNAC vs TLRY · P/E 2.1, rev $78.0K vs rev $915.5M
Cartesian Therapeutics Inc. (RNAC) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Cartesian Therapeutics Inc. (RNAC) is a biotechnology company listed on US.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported RNAC revenue for 2026-06-30 was $78.0K. Net income was -$23.4M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
Latest reported TLRY revenue for 2026-05-31 was $915.5M. Net income was -$121.4M. Revenue was up 11.5% from 2025-05-31 to 2026-05-31. TLRY currently screens at market cap $573.9M.
RNAC currently screens at market cap $290.9M and trailing P/E 2.1. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the RNAC and TLRY stock pages for the full models.
Not investment advice.